Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China flag China · Delayed Price · Currency is CNY
4.850
+0.500 (11.49%)
Nov 5, 2026, 3:04 PM CST

Xiangxue Pharmaceutical Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
165.45254.57131.74149.32166.5196.12
Short-Term Investments
--13--105.42
Trading Asset Securities
----0.1365.63
Cash & Short-Term Investments
165.45254.57144.74149.32166.63367.17
Cash Growth
31.50%75.88%-3.06%-10.39%-54.62%-44.58%
Accounts Receivable
912.23798.98844.23794.44701.71,220
Other Receivables
38.3531.3557.5352.5576.47346.04
Receivables
950.58830.33901.76846.99778.171,566
Inventory
274.44295.43340.92411.3467.07761.46
Other Current Assets
222.45224.69215.28416.74281.32390.9
Total Current Assets
1,6131,6051,6031,8241,6933,086
Property, Plant & Equipment
3,5173,6344,2604,6214,8085,957
Long-Term Investments
91.0695.21123.44178.48472.03270.21
Goodwill
199.72199.72199.72199.72199.72266.6
Other Intangible Assets
706.45737.57840.4919.28964.091,034
Long-Term Deferred Tax Assets
9.539.3719.6628.4233.3519.37
Long-Term Deferred Charges
282.11262.34248.82476.81440.65429.51
Other Long-Term Assets
213.08201.44203.7433.0830.95318
Total Assets
6,6316,7457,4988,2818,64211,381

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
1,1871,1851,1541,087988.951,123
Accrued Expenses
75.71400.46228.41116.84112.3972.82
Short-Term Debt
807.32882.61,3551,4981,9262,466
Current Portion of Long-Term Debt
555.29115.93282.98340.3376.73447.6
Current Portion of Leases
-3.753.353.633.252.9
Current Income Taxes Payable
139.7739.6121.7315.168.149.1
Current Unearned Revenue
55.4132.97152.94162.81249.79117.38
Other Current Liabilities
4,0823,4102,1841,9381,8682,705
Total Current Liabilities
6,9026,1715,3825,1625,2336,944
Long-Term Debt
-437.44570.64556426.93528.92
Long-Term Leases
24.7227.1230.8834.9224.922.36
Long-Term Unearned Revenue
51.7250.8953.1860.4260.3565.65
Long-Term Deferred Tax Liabilities
5.826.618.129.466.623.73
Other Long-Term Liabilities
12.778.1614.74144.92170.0677.86
Total Liabilities
6,9976,7016,0605,9675,9227,623

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
661.28661.28661.28661.28661.28661.36
Additional Paid-In Capital
2,1522,1522,1522,1522,1522,152
Retained Earnings
-3,537-3,123-1,731-882.06-493.1138.42
Treasury Stock
-8.5-8.5-8.5-8.5-8.5-8.77
Comprehensive Income & Other
-41.29-42.34-19.281.69-5.192.07
Total Common Equity
-772.9-360.321,0551,9252,3072,946
Minority Interest
406.9404.27383.93388.52413.22812.23
Shareholders' Equity
-36643.951,4392,3132,7203,758
Total Liabilities & Equity
6,6316,7457,4988,2818,64211,381

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
1,3871,4672,2432,4332,4583,448
Net Cash (Debt)
-1,222-1,212-2,098-2,284-2,291-3,081
Net Cash Growth
------
Net Cash Per Share
-1.84-1.84-3.18-3.46-3.46-4.65
Filing Date Shares Outstanding
678.17665.18661.74645.14659.23958.52
Total Common Shares Outstanding
678.17665.18661.74645.14659.23958.52
Working Capital
-5,290-4,566-3,779-3,337-3,540-3,858
Book Value Per Share
-1.14-0.541.592.983.503.07
Tangible Book Value
-1,679-1,29814.78805.71,1431,645
Tangible Book Value Per Share
-2.48-1.950.021.251.731.72
Buildings
-3,4903,8643,4423,4953,709
Machinery
-991.33990.741,0431,040946.22
Construction In Progress
-503.79614.631,2141,1802,106